ATAD5

Across TCGA pan-cancer cohorts, ATAD5 mass-spec protein is linked to patient survival in 2 of 34 cancer types, making it a survival-associated ATAD5 data layer compared with 27 for mass-spec protein and 9 for mutation status.

The strongest signal is observed in pancreatic ductal adenocarcinoma (PDAC), where higher ATAD5 mass-spec protein is associated with worse disease-free survival. In most high-consensus cancer types, elevated ATAD5 expression acts as an unfavorable survival marker, although some lineages such as LSCC show a favorable association.

PDAC and LSCC are the cancer types where ATAD5 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
PDAC	DFS	Median	All	0.222	0.575	.004	22	view →
LSCC	OS	Median	All	0.892	0.707	.014	8	view →

Pink = unfavorable, green = favorable. Showing the 2 strongest of 2 lineages.

ATAD5–PDAC (DFS)

Open the PDAC breakdown →